Austin, TX — January 21, 2025

Akexis, a biopharmaceutical company dedicated to advancing transformative cancer therapeutics, proudly introduces Dr. Suzanne Kennedy as Chief Executive Officer. With extensive experience in cancer research, product development, and strategic partnerships, Dr. Kennedy’s journey to Akexis is marked by a deep commitment to improving care for patients facing life-threatening conditions.

Dr. Kennedy’s passion for cancer research began early in life when she witnessed the heartbreaking loss of a young neighbor to leukemia. This formative experience motivated her to pursue a career in life sciences. After earning her doctorate in microbiology and immunology, she honed her business acumen through leadership roles in marketing, business development, and R&D in biotechnology and life science companies developing tools for research.

She returned to cancer research at Baylor College of Medicine in Houston, pursuing independent studies at the Alkek Center for Metagenomics and Microbiome Research, where she developed a program to study the connection between the gut microbiome and pancreatic cancer. This work led her to join Bio-Path Holdings, where she played a crucial role in driving innovative clinical programs and defining expansion strategies for a novel oncology therapeutic platform.

Building on her experience in cancer therapeutics, Dr. Kennedy then took on a leadership role at GlycosBio, leading R&D initiatives focused on creating medical foods for patients with compromised digestive health. Her work addressed the nutritional challenges often faced by patients undergoing rigorous medical treatments.

Dr. Kennedy’s career continued at ViuHealth, where she oversaw pharmaceutical partnerships and strategic initiatives. Her leadership contributed to the successful execution of clinical trials and significantly strengthened the company’s market presence in the pharmaceutical sector.

Now, as Chief Executive Officer of Akexis, Dr. Kennedy is leveraging her extensive background to guide the development of groundbreaking cancer therapeutics for late-stage cancer patients. Her expertise in research, business development, and strategic execution is instrumental in advancing Akexis’ mission to address critical unmet needs in oncology care. “Throughout my career, I’ve seen how innovation and science can bring hope to patients facing the toughest battles,” said Dr. Kennedy. “Joining Akexis is a continuation of my commitment to delivering transformative therapies for those who need it most.”

Dr. Kennedy’s leadership, alongside Akexis Founder and Chief Scientific Officer Dr. Lingbing Zhang, underscores the company’s dedication to pioneering solutions that offer hope to cancer patients worldwide.

For more information, please visit www.akexis.com.